References
- Zadnik V, Primic Zakelj M, Lokar K, Jarm K, Ivanus U, Zagar T, et al. Cancer burden in Slovenia with the time trends analysis. Radiol Oncol 2017; 51: 47-55. 10.1515/raon-2017-0008
- Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non–small-cell lung cancer. J Clin Oncol 2010; 28: 2181-90. 10.1200/JCO.2009.26.2543
- Pless M, Stupp R, Ris H-B, Stahel RA, Weder W, Thiersteinet S, et al. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet 2015; 386: 1049-56. 10.1016/S0140-6736(15)60294-X
- Eberhardt WEE, Pöttgen C, Gauler TC, Friedel G, Veit S, Heinrichet V, et al. Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non–small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE). J Clin Oncol 2015; 33: 4194-201. 10.1200/JCO.2015.62.6812
- Bradley JD, Paulus R, Komaki R, Masters G, Blumenscheinet G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p. Lancet Oncol 2015; 16: 187-99. 10.1016/S1470-2045(14)71207-0
- Garon EB, Naiyer AR, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med 2015; 372: 2018-28. 10.1056/NEJMoa1501824
- Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med 2015; 373: 123-35. 10.1056/NEJMoa1504627
- Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med 2016; 375: 1823-33. 10.1056/NEJMoa1606774
- Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 2017; 18: 895-903. 10.1016/S1470-2045(17)30380-7
- Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med 2017; 377: 1919-29. 10.1056/NEJMoa1709937
- Albain KS, Crowley JJ, Turrisi AT, Gandara DR, Farrar WB, Clark JI, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non–small-cell lung cancer: a southwest oncology group phase II study, SWOG 9019. J Clin Oncol 2002; 20: 3454-60. 10.1200/JCO.2002.03.055
- National Institute of Cancer. Common terminology criteria for adverse events (CTCAE) common terminology criteria for adverse events v3.0 (CTCAE). [cited 2017 Nov 2]. Available at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. NIH Publ2010; 2009: 0-71. 10.1080/00140139.2010.489653
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. JNCI 2000; 92: 205-16. 10.1093/jnci/92.3.205
- Vrankar M, Zwitter M, Kern I, Stanic K. PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients after chemoradiotherapy. Neoplasma 2018; 59: 101-6. 10.4149/neo_2018_170206N77
- Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374: 379-86. 10.1016/S0140-6736(09)60737-6
- 16Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et
al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. AnnOncol 2017; 28 (Suppl 4): iv1-21. 10.1093/annonc/mdx222PostmusPEKerrKMOudkerkMSenanSWallerDAVansteenkisteJEarly and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†Ann Oncol2017284iv12110.1093/annonc/mdx222
- Kovač V, Smrdel U. Meta-analyses of clinical trials in patients with non-small cell lung cancer. Neoplasma 2004; 51: 334-40.
- Tsujino K, Kurata T, Yamamoto S, Kawaguchi T, Kubo A, Isa S, et al. Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non–small-cell lung cancer?: A pooled analysis of the literature. J Thorac Oncol 2013; 8: 1181-9. 10.1097/JTO.0b013e3182988348
- Luo H, Yu X, Liang N, Xie J, Deng G, Liu Q, et al. The effect of induction chemotherapy in patients with locally advanced nonsmall cell lung cancer who received chemoradiotherapy. Medicine 2017; 96: e6165. 10.1097/MD.0000000000006165
- Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008; 26: 2450-6. 10.1200/JCO.2007.14.4824
- Wozniak AJ, Moon J, Thomas CR, Kelly K, Mack PC, Gaspar LE, et al. A pilot trial of cisplatin/etoposide/radiotherapy followed by consolidation docetaxel and the combination of bevacizumab (NSC-704865) in patients with inoperable locally advanced stage III non–small-cell lung cancer: SWOG S0533. Clin Lung Cancer 2015; 16: 340-7. 10.1016/j.cllc.2014.12.014
- Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, et al. Anti-pd-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol 2013; 86: 343-9. 10.1016/j.ijrobp.2012.12.025
- Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014; 124: 687-95. 10.1172/JCI67313
- Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014; 74: 5458-68. 10.1158/0008-5472.CAN-14-1258
- Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy. Lancet Oncol 2015; 16: e498-509. 10.1016/S1470-2045(15)00007-8
- Park SS, Dong H, Liu X, Harrington SM, Krco CJ, Grams MP, et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res 2015; 3: 610-9. 10.1158/2326-6066.CIR-14-0138
- Lumniczky K, Sáfrány G. The impact of radiation therapy on the antitumor immunity: local effects and systemic consequences. Cancer Lett 2015; 356: 114-25. 10.1016/j.canlet.2013.08.024
- Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol 2015; 1: 1325. 10.1001/jamaoncol.2015.2756
- Derer A, Frey B, Fietkau R, Gaipl US. Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors. Cancer Immunol Immunother 2016; 65: 779-86. 10.1007/s00262-015-1771-8
- Fujimoto D, Uehara K, Sato Y, Sakanou I, Ito M, Teraoka S, et al. Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. Sci Rep 2017; 7: 11373. 10.1038/s41598-017-11949-9
- Hallahan D, Kuchibhotla J, Wyble C. Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res 1996; 56: 5150-5.
- Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res 2015; 3: 345-55. 10.1158/2326-6066.CIR-14-0196
- Kachikwu EL, Iwamoto KS, Liao Y-P, DeMarco JJ, Agazaryan N, Economou J, et al. Radiation enhances regulatory T cell representation. Int J Radiat Oncol 2011; 81: 1128-35. 10.1016/j.ijrobp.2010.09.034
- Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, K.Wansley E, al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006; 203: 1259-71. 10.1084/jem.20052494
- Vanpouille-Box C, Diamond JM, Pilones KA, Zavadil J, Babb JS, Formenti, SC, et al. TGF is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res 2015; 75: 2232-42. 10.1158/0008-5472.CAN-14-3511
- Velcheti V, Schalper Ka, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Investig 2014; 94: 107-16. 10.1038/labinvest.2013.130
- Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, et al. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer 2015; 89: 181-8. 10.1016/j.lungcan.2015.05.007
- Wang A, Wang HY, Liu Y, Zhao MC, Zhang HJ, Lu ZY, et al. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a metaanalysis. Eur J Surg Oncol 2015; 41: 450-6. 10.1016/j.ejso.2015.01.020
- Zhou Z, Zhan P, Song Y. PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res 2015; 4: 203-2082015; 4: 203-8. 10.3978/j.issn.2218-6751.2015.03.02
- Herbst RS, Soria J, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-7. 10.1038/nature14011